Truist Securities Maintains Buy on Neurocrine Biosciences, Raises Price Target to $213

Benzinga Newsdesk www.benzinga.com Positive 88.3%

Neg 0% Neu 0% Pos 88.3%

Truist Securities analyst Danielle Brill maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $200 to $213.